A pilot study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that for people with borderline resectable pancreatic cancer, administrating an immunotherapy drug in combination with chemotherapy ...
Apr 5, 2024
0
2
A specific genetic alteration, known as an ALK fusion, drives non-small cell lung cancer in some patients. This abnormality leads to excessive activity of the ALK protein, a key cancer promoter. These tumors can be treated ...
Apr 16, 2024
0
26
A drug that targets a protein known as phosphatidylserine boosted the response rate for hepatocellular carcinoma (HCC) patients receiving immunotherapy without compromising their safety, according to results of a phase two ...
22 hours ago
0
52
For patients with advanced adrenocortical carcinoma, cabozantinib shows promising efficacy, according to a study published online April 9 in The Lancet Oncology.
Apr 29, 2024
0
1
